We're still delving into doomsday hypotheticals. You said corporate needs to announce a deal within weeks. Where did that come from? What I believe is management mapped out their strategy as far back as late 2017. It was that time frame I spoke to Alfred Wong in regards to Breathtec's plan for an aquisition but Wong refused to go into details. However, if you go back through the posts you will see this board talked up an aquisition of Nash Pharmacueticals well before management actually pulled the trigger. The problem I had with the deal before it was done was of course a reverse split and the fact Nash Pharmaceuticals offered zero proof there was anything worth handing over our shares to aquire. We did not know management had scooped up Dr. Mark Williams research (5 years) and decided to take Nash Pharmacueticals in a completely different direction - versus another potstock scheme. As it all began to unfolded, we got to start unpacking exactly what we had just purchased with half our shares. Without question, I do not like the fact Kal regained shareholder control at shareholders expense. Kal robbed us blind with his previous antics. I question if his prior selloff and departure was a part of a scheme down the road with Nash Pharmacueticals. However, I do believe the encounter between Chris Moreau (CEO) and Doc Williams did take the whole plan in another direction. One that has a legitimate shot at striking the iron while it's hot. Algernon Pharmaceuticals is in the hottest space in phara world for chasing molecules. I'm thinking this deal will further unfold just like it started - in rapid fashion. We have received an unprecedented number of positive news releases. All moving rapidly towards clinical trials. Having said that, I can't see longs being cleaned out yet again by massive dilution and/or another reverse split. Another split means longs will likely never recover thier seed money. Much less make a profit. So that's not what I'm fixated on at this juncture. I was looking for some patent applications to be filed and whalla...we got news of multiple provisional patents tucked into the monthly report. Folks still twisted it into a negative by saying anyone can file a provisional. Agreed, but is it better to know we did versus did not? I mean there were folks going so far to say we could not patent repurposed drugs. They lost that argument and turned to more nonsense. The patent applications could have been a news release unto itself. Anyhoo, it remains my belief these guys are going to get a deal or two out of this by the time we get to trials tha cost a gorilla grip. Keeping in mind the preclinicals do add value to the pipeline >`>`>` That's how we may be in position to also go after IPF. No biggie. Just another billion dollar market. So, do we want all the answers like yesterday? Sure we do. But folks would be hard pressed to say management is just sitting on thier @ss doing nothing. We have plenty proof of the opposite in black and white. In Pharma World 6 Months is not an eternity. We have come a long way in a short time. Where might we be in 6 Months is anybody's guess at this moment, but what's the alternative? Sit on the sidelines? Sell your shares? I'm already in too deep and selling shares now would be sheer madness. Beyond the pharm side of the coin nobody wants to discuss our supposed breathalyzer which I have stated is in better position to monetize than Cannabix. If management came clean on that story the stock would likely already be over $1 USD. I believe their burying the narrative for the sake of Cannabix's shareholders. It's a Kal Malhi ego trip. IMO, it's pure insanity to have an overall valuation of Algernon Pharmaceuticals anywhere from 3M to 10M USD. Currently we're headed back to the 3M range. That's pre-split 3 cent range. Criminal.
/////AMG
